Use of dopamine agonists in the treatment of Parkinson's disease
Gekht, A.B.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
2002
ISSN/ISBN: 1997-7298 PMID: 12378886 Document Number: 542345
Document emailed within 1 workday
Related Documents
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Krivonos, O.V.; Fedorova, N.V.; Chigir', I.P. 2004: A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 24-30
Löschmann, P.A.; Kunow, M.; Wachtel, H. 1992: Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease Journal of Neural Transmission. Supplementum 38: 55-64
Albin, R.L.; Nichols, T.E.; Frey, K.A. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311
Ahlskog, J.Eric.; Maraganore, D.M.; Uitti, R.J.; Uhl, G.R. 2002: Brain imaging to assess the effects of dopamine agonists on progression of Parkinson disease JAMA 288(3): 311; Author Reply 312-3
Szczudlik, A.; Rudzińska, M. 2007: Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes Neurologia i Neurochirurgia Polska 41(2 Suppl 1: S6-S9
Rasmussen, V.G.; Poulsen, S.H.; Dupont, E.; Østergaard, K.; Safikhany, G.; Egeblad, H. 2009: Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study Journal of Heart Valve Disease 18(4): 463-469
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302
Tadori, Y.; Kobayashi, H. 2014: The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors Nihon Shinkei Seishin Yakurigaku Zasshi 34(5-6): 127-132
Kohli, J.D.; Weder, A.B.; Goldberg, L.I.; Ginos, J.Z. 1980: Structure activity relationships of N-substituted dopamine derivatives as agonists of the dopamine vascular and other cardiovascular receptors Journal of Pharmacology and Experimental Therapeutics 213(2): 370-374
Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Kish, S.; Rajput, A.; Gilbert, J.; Rozdilsky, B.; Chang, L.J.; Shannak, K.; Hornykiewicz, O. 1987: GABA-dopamine relationship in Parkinson's disease striatum Advances in Neurology 45: 75-77
Stoessl, A.J.; de la Fuente-Fernández, R.úl. 2003: Dopamine receptors in Parkinson's disease: imaging studies Advances in Neurology 91: 65-71
Gerfen, C.R. 2000: Dopamine-mediated gene regulation in models of Parkinson's disease Annals of Neurology 47(4 Suppl 1): S42
Christensen, A.V.; Nielsen, I.M. 1980: Dopaminergic supersensitivity: influence of dopamine agonists and drugs used for the treatment of tardive dyskinesia Advances in Biochemical Psychopharmacology 24: 341-349
Melamed, E. 1995: Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum? Journal of Neural Transmission. Supplementum 45: 57-60